Dermozolon is a glucocorticosteroid preparation used to treat skin diseases.
Release form and composition
Dermozolon is produced in the form of a uniform soft yellow-brown ointment, in tubes of 5 g each. The product has a weak, specific odor.
One gram of ointment contains 30 mg of clioquinol in a hydrophilic ointment base, 5 mg of prednisolone and excipients - vaseline, cetyl alcohol, wax, polysorbate 60, methyl parahydroxybenzoate and liquid paraffin.
Indications for use
The drug is used to treat eczema, diaper rash and other dermatitis, which are accompanied by allergic inflammation, complicated by a bacterial or fungal infection.
Also Dermozolon is prescribed to patients with superficial limited bacterial or fungal infections of the skin, accompanied by allergic inflammation, with the ineffectiveness of previous therapy with antibacterial and antifungal drugs.
The use of Dermozolon is contraindicated in cases of hypersensitivity to the components included in its composition. The drug is not prescribed to children under two years, as well as with:
- Pulmonary tuberculosis;
- Fungal, viral, or bacterial skin lesions;
- Skin tumors.
The purpose of the drug during pregnancy and during the period of lactation is possible only according to indications and only in cases where the expected effect from the use of ointment far exceeds the potential risk to the child or the developing fetus.
Dosing and Administration
Dermozolon should be applied with a thin layer to the affected skin twice or three times a day.
The instructions for Dermozolon indicate that the drug, like other glucocorticosteroids, may cause systemic side effects, namely:
- Suppression of the function of the adrenal cortex;
- Steroid myopathy;
- Decreased resistance to infections;
- Violations of water and electrolyte balance;
- Osteopenia with compression fractures of the vertebral bodies;
- Ophthalmic disorders;
- The occurrence or increase of arterial hypertension;
- Sleep disturbances;
- Face rounding;
- Excessive sweating;
- Disruption of the menstrual cycle;
- Benign intracranial hypertension;
- Weight gain;
- Purple Striae;
- Skin atrophy;
- Ischemic bone necrosis.
Cases of overdose Dermozolon currently not registered.
The drug does not affect the patient's ability to engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
It is important when applying Dermozolon not to allow the drug to enter the mucous membranes and eyes. Keep in mind that the ointment can stain clothes.
Drug synonyms are not released. Analogs of Dermozolon are Foster, Maksitrol, Kandibiotik, Diprogent, Ambene, Tobradex, Bemilon, Kleore and Sinalar K.
Terms and conditions of storage
The instructions to Dermozolon indicated that the drug should be stored in a dark, dry and inaccessible to children place, at a temperature varying between 2-15 ° C.
From pharmacies, the drug is released on prescription. The shelf life of the drug is two years.